Skip to main content

Table 3 Responses at EOT and secondary timepoints in the MITT population and early switch subpopulation

From: Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial

  MITT population Early switch subpopulation
(n = 250) (n = 102)
Response n/N (%) [95% CI]a n/N (%) [95% CI]a
Global response at EOT   
 Success 170/203 (83.7) [78.7–88.8] 81/ 90 (90.0) [83.8–96.2]
 Sensitivity analysis* 170/250 (68.0) [62.2–73.8] 81/102 (79.4) [71.6–87.3]
 Failure 33 9
 Missing/unknown 47 12
Clinical response at EOT   
 Success 174/187 (93.0) [89.4–96.7] 83/ 89 (93.3) [88.0–98.5]
 Sensitivity analysis* 174/250 (69.6) [63.9–75.3] 83/102 (81.4) [73.8–88.9]
 Failure 13 6
 Missing/unknown 63 13
Microbiological response at EOT   
 Success 183/192 (95.3) [92.3–98.3] 87/ 90 (96.7) [93.0–100.0]
 Sensitivity analysis* 183/250 (73.2) [67.7–78.7] 87/102 (85.3) [78.4–92.2]
 Failure 9 3
 Missing/unknown 58 12
Global response at secondary time points n/N (%) [95% CI] n/N (%) [95% CI]
 EOIV 208/235 (88.5) [84.4–92.6] 97/101 (96.0) [92.2–99.8]
  Sensitivity analysis* 208/250 (83.2) [78.6–87.8] 97/102 (95.1) [90.9–99.3]
 Week 2 follow-up 148/194 (76.3) [70.3–82.3] 72/ 86 (83.7) [75.9–91.5]
  Sensitivity analysis* 148/250 (59.2) [53.1–65.3] 72/102 (70.6) [61.7–79.4]
 EOS 131/187 (70.1) [63.5–76.6] 68/ 86 (79.1) [70.5–87.7]
  Sensitivity analysis* 131/250 (52.4) [46.2–58.6] 68/102 (66.7) [57.5–75.8]
  1. *Missing/unknown values set as failures; a95% CI based on normal approximation to the binomial.
  2. Abbreviations used: CI, confidence interval; EOIV, end of intravenous treatment; EOS, end of study; EOT, end of treatment; MITT, modified intent-to-treat.